Printed From BioPortfolio.com
Immuno-Oncology Drug Development -- Too Much Of A Good Thing?
05:53 EST 12 Dec 2017 | Forbes
There are more than 2,000 immune-boosting cancer treatments in clinical trials, a new study finds. That raises both hopes and concerns about the future of this promising field of oncology research.
Original Article: Immuno-Oncology Drug Development -- Too Much Of A Good Thing?
